At ECTRIMS 2025, the professor of neurology at Karolinska Institutet provided clinical insights on results from the phase 3 RIDOSE-MS trial of yearly rituximab in relapsing-remitting multiple sclerosis. [WATCH TIME: 5 minutes]
Anders Svenningsson, MD, PhD
Advertisement
Professor of neurology in the Department of Clinical Sciences at Karolinska Institutet.
Articles by Anders Svenningsson, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Fenebrutinib Hits Key Phase 3 Marks in Relapsing and Primary Progressive MS
2
FDA Clears Phase 2a Clinical Trial to Test JOTROL in Patients With Parkinson Disease
3
OnabotulinumtoxinA Fails to Meet Primary End Point in Phase 3 PRECLUDE Trial for Episodic Migraine
4
Phase 2 VIBRANCE-2 Findings Further Support Orexin-Targeting Treatment Alixorexton in Narcolepsy
5
